CN110590919B - 含鸟氨酸的短肽及其应用 - Google Patents
含鸟氨酸的短肽及其应用 Download PDFInfo
- Publication number
- CN110590919B CN110590919B CN201910836442.2A CN201910836442A CN110590919B CN 110590919 B CN110590919 B CN 110590919B CN 201910836442 A CN201910836442 A CN 201910836442A CN 110590919 B CN110590919 B CN 110590919B
- Authority
- CN
- China
- Prior art keywords
- asp
- bacillus megaterium
- short peptide
- asp asp
- orn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 46
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 title claims abstract description 19
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 title claims abstract description 19
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 229960003104 ornithine Drugs 0.000 title claims abstract description 19
- 241000228197 Aspergillus flavus Species 0.000 claims abstract description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 241000194107 Bacillus megaterium Species 0.000 description 54
- OZRFYUJEXYKQDV-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound OC(=O)CC(N)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(O)=O OZRFYUJEXYKQDV-UHFFFAOYSA-N 0.000 description 20
- 229930195730 Aflatoxin Natural products 0.000 description 14
- 239000005409 aflatoxin Substances 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 11
- 244000105624 Arachis hypogaea Species 0.000 description 11
- 235000020232 peanut Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 235000017060 Arachis glabrata Nutrition 0.000 description 4
- 235000010777 Arachis hypogaea Nutrition 0.000 description 4
- 235000018262 Arachis monticola Nutrition 0.000 description 4
- VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 4
- QOVWVLLHMMCFFY-ZLUOBGJFSA-N Asp-Asp-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QOVWVLLHMMCFFY-ZLUOBGJFSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VPSHHQXIWLGVDD-ZLUOBGJFSA-N Asp-Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VPSHHQXIWLGVDD-ZLUOBGJFSA-N 0.000 description 2
- 208000003643 Callosities Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 241000339094 Aspergillus flavus NRRL3357 Species 0.000 description 1
- 241000228230 Aspergillus parasiticus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 229930020125 aflatoxin-B1 Natural products 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了一种含鸟氨酸的短肽及其应用，属于生物技术领域，该短肽能够有效应用于抑制黄曲霉的生长和黄曲霉毒素的生物合成中。该短肽具有如下通式结构：
其中，X代表鸟氨酸，n＝1，m为1‑8的正整数。本发明能够应用于黄曲霉生长的抑制中。
Description
技术领域
本发明属于生物技术领域，尤其涉及一种含鸟氨酸的短肽及其应用。
背景技术
黄曲霉毒素主要由黄曲霉和寄生曲霉产生，具有强的毒性、致畸性和致癌性，农作物如花生、玉米、大米、棉籽、坚果等容易被黄曲霉毒素污染。黄曲霉毒素B1是已知毒性最强的天然致癌物，其主要引发肝癌。
现在常用物理、化学、生物法去除原料中的黄曲霉毒素。物理法如加热、吸附、提取、伽马射线辐照、紫外线照射等。化学法如用臭氧、氨水、氯气、过氧化氢、甲醛处理等。生物法如用微生物发酵原料去毒，用植物提取物抑制毒素产生等。然而，每种方法都有限制，或因原料的营养受到损失，或因需要昂贵的设备等。例如，黄曲霉毒素结构非常稳定，270℃分解，如用加热处理是一般温度越高、加热时间越长，黄曲霉毒素去除率越高，但很明显，加热法容易使物料的营养损失，且需要耐高压的设备。因此，目前急需提供一种有效的方法来抑制黄曲霉毒素的生物合成。
发明内容
本发明提供了一种含鸟氨酸的短肽及其应用，该短肽能够有效应用于黄曲霉的生长和黄曲霉毒素的生物合成中。
为了达到上述目的，本发明的一方面提供了一种含鸟氨酸的短肽，所述短肽具有如下通式结构：
其中，X代表鸟氨酸，n＝1，m为1-8的正整数。
作为优选技术方案，所述短肽的氨基酸序列选自序列表中SEQ ID NO.17、SEQ IDNO.18、SEQ ID NO.19、SEQ ID NO.20、SEQ ID NO.21、SEQ ID NO.22、SEQ ID NO.23、SEQ IDNO.24中的任意一种。
本发明的另一方面提供了一种如上述任一项技术方案所述的短肽在固体培养基上抑制黄曲霉生长中的应用。
本发明的再一方面提供了一种如上述任一项技术方案所述的短肽在农作物储存中抑制黄曲霉的生长和黄曲霉毒素的生物合成中的应用。
本发明的又一方面提供了一种抗菌组合物，所述抗菌组合物包括至少一种治疗或预防有效量的如上述任一项技术方案所述的短肽和至少一种的药学上可接受的载体。
与现有技术相比，本发明的优点和积极效果在于：
1、本发明所提供的短肽为从巨大芽孢杆菌发酵液中首次分离得到的，具有很好的黄曲霉毒素的抑制作用。
2、本发明所提供的短肽不仅在固体培养基上对黄曲霉的生长具有显著的抑制作用，而且在农作物储存中也对黄曲霉的生长和黄曲霉毒素的生物合成具有显著的抑制作用，其中，部分短肽在2mg/mL的浓度时即可显著抑制黄曲霉的生长。
附图说明
图1为本发明实施例1中所提供的经Sephadex G-25层析分离得到的巨大芽孢杆菌发酵液的组分纯化图，包括A1和A2两个组分；
图2为本发明实施例1所提供的A2组分经反相高效液相色谱的分离纯化图，包括B1-B9共9个组分；
图3为本发明实施例1所提供的巨大芽孢杆菌中各短肽的液质联用色谱图，其中，图(a)为经反相高效液相色谱分离得到的B6组分的液质图；(b)为m/z 942.9606的短肽的质谱图；(c)为m/z 938.0045的短肽的质谱图。
图4为本发明实施例2所提供的不同构型的Asp-Orn、Asp-Asn和Asp-Asp-Asn在农作物储存中的抑菌效果图；
图5为本发明实施例2所提供的扫描电镜下观察得到的L-Asp-L-Orn对于黄曲霉菌菌丝形态的影响；
图6为本发明实施例2所提供的透射电镜下观察得到的L-Asp-L-Orn对于黄曲霉菌菌丝形态的影响。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
实施例1
本发明实施例提供了一种含鸟氨酸的短肽，该短肽从巨大芽孢杆菌发酵液中首次分离，具体如下:
所利用的微生物：
黄曲霉A.flavus NRRL 3357：培养于PDA培养基中(200g土豆浸提物，20g葡萄糖，20g琼脂，1L水)。
巨大芽孢杆菌Bacillus megaterium(CGMCC7086，保存于中国微生物菌种保藏管理委员会普通微生物中心)：培养于牛肉膏蛋白胨培养基中(牛肉膏3g，蛋白胨10g，氯化钠5g，1L水)。
纯化和鉴定:
培养12升巨大芽孢杆菌(160rpm，37℃，3天)，发酵液经8,000r/min离心20分钟。将离心后的上清液经80％硫酸铵沉淀，沉淀冷冻干燥后，经Sephadex G-25层析，流速为5mL/min，检测波长为220nm。如图1所示，沉淀中共有两个组分，实验表明A2组分具有抑制黄曲霉的作用，收集A2组分进一步研究。
将A2组分进一步经反相高效液相色谱(RP-HPLC)(Agilent,Santa Clara,CA,USA)纯化，所采用的色谱柱为C18柱(25×250mm)，流动相为含0.1％三氟乙酸(TFA)的乙腈。如图2所示，共收集9个组分，实验表明B6组分具有抑制黄曲霉的作用，收集B6组分进一步研究。
将B6组分进一步经液质联用色谱(LC-MS/MS)鉴定，所采用的仪器为AccurateMass quadruple time-of-flight(Q-TOF)Liquid Chromatography(Triple TOF 5006,ABSCIEX,USA)。如图3可知，鉴定出3种短肽，分别为Asp-peptide、Asn-peptide和Orn-peptide，这3种短肽分别包含了多种含2-7个Asp(天冬氨酸残基)的短肽。实验表明，Asp-peptide、Asn-peptide和Orn-peptide对黄曲霉具有抑制作用。
结合谱图分析可知，所述短肽具有如下通式结构：
其中，X代表鸟氨酸，n＝1，m为1-8的正整数。
根据上述条件进行分类，所得到的短肽在不同情况下均为一系列短肽，具体如下：
| 序列号 | 短肽 |
| SEQ ID NO.17 | Asp-Orn |
| SEQ ID NO.18 | Asp-Asp-Orn |
| SEQ ID NO.19 | Asp-Asp-Asp-Orn |
| SEQ ID NO.20 | Asp-Asp-Asp-Asp-Orn |
| SEQ ID NO.21 | Asp-Asp-Asp-Asp-Asp-Orn |
| SEQ ID NO.22 | Asp-Asp-Asp-Asp-Asp-Asp-Orn |
| SEQ ID NO.23 | Asp-Asp-Asp-Asp-Asp-Asp-Asp-Orn |
| SEQ ID NO.24 | Asp-Asp-Asp-Asp-Asp-Asp-Asp-Asp-Orn |
需要说明的是，上述所示的序列SEQ ID NO.17-SEQ ID NO.24中，由于鸟氨酸本身并没有与之相对应的密码子，其均是由精氨酸通过精氨酸分解酶分解得到的，因此，在对应的氨基酸序列中，鸟氨酸对应的密码子均表述为精氨酸所对应的密码子，该表述方法在实际科研工作中是可行的，这主要是因为在实际科研工作中，为了得到鸟氨酸，本领域技术人员也是通过对精氨酸进行处理得到。
可以理解的是，在上述组分分离鉴定中，从B6组分中还鉴定得到了：
CA肽(Asp-Asp-Asp-Asp-Asp-Asp-Asp-2-羟基-辛酸-)；和
His肽(Asp-Asp-Asp-Asp-Asp-Asp-Asp-His-，其为由组氨酸上的α-氨基基团和天冬氨酸上的α-羰基基团形成的环)。但由于上述两种肽对黄曲霉的抑菌效果不显著，因此不作保护，但不排除上述两种肽对于其他菌的抑制效果。
实施例2
在农作物储存中的抑菌试验
本实施例中的农作物可为花生、玉米、大米、棉籽、坚果等，其中，以花生储存为例，具体如下：
本实施例仅以Asp-Orn、Asp-Asn和Asp-Asp-Asn为例进行测试，同时，为了判断每种肽的构型对于抑菌效果的影响，还分别以上述3种肽为例进行了不同构型的合成。将所得到的不同构型的短肽配成不同浓度的溶液，喷洒到花生上，28℃培养7天，观察黄曲霉的生长状况(作为对照比较：每个花生上同时接种105个黄曲霉孢子)。
由图4可知，与对照相比，抑制作用最强的是L-Asp-L-Orn,L-Asp-L-Asn和L-Asp-L-Asp-L-Asn，且相对于D型的短肽，L型的短肽效果更加显著，在达到2mg/mL时即可更加显著抑制黄曲霉在花生上的生长以及显著抑制黄曲霉毒素在花生上的生成。以L-Asp-L-Orn为例，如图5-6所示，显示了其对于黄曲霉菌菌丝形态的影响，A、B为对照组菌丝，C、D为短肽处理组菌丝，其中，在A、B组中，菌丝的细胞形态饱满，各细胞器清晰完整，而C、D组中，菌丝的细胞形态发生变化，液泡变大，细胞器变型。由此可说明，本实施例所提供的短肽可有效抑制黄曲霉在花生上的生长以及黄曲霉毒素在花生上的生成。
实施例3
基于实施例2，本施例还提供了一种抗菌组合物，所述抗菌组合物包括如上述实施例所述的至少一种治疗或预防有效量的如SEQ ID NO:1-SEQ ID NO.24所示氨基酸序列的短肽和至少一种的药学上可接受的载体。由于上述实施例所提供的24种短肽可有效抑制黄曲霉在花生上的生长以及黄曲霉毒素在花生上的生成，因此，配合至少一种的药学上可接受的载体组成的抗菌组合物也可有效应用在黄曲霉的抑制中，尤其是农作物储存中的黄曲霉以及黄曲霉毒素的生长。
序列表
<110> 中国海洋大学
<120> 含鸟氨酸的短肽及其应用
<160> 24
<170> PatentIn version 3.3
<210> 1
<211> 2
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 1
Asp Asp
1
<210> 2
<211> 3
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 2
Asp Asp Asp
1
<210> 3
<211> 4
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 3
Asp Asp Asp Asp
1
<210> 4
<211> 5
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 4
Asp Asp Asp Asp Asp
1 5
<210> 5
<211> 6
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 5
Asp Asp Asp Asp Asp Asp
1 5
<210> 6
<211> 7
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 6
Asp Asp Asp Asp Asp Asp Asp
1 5
<210> 7
<211> 8
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 7
Asp Asp Asp Asp Asp Asp Asp Asp
1 5
<210> 8
<211> 9
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 8
Asp Asp Asp Asp Asp Asp Asp Asp Asp
1 5
<210> 9
<211> 2
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 9
Asp Asn
1
<210> 10
<211> 3
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 10
Asp Asp Asn
1
<210> 11
<211> 4
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 11
Asp Asp Asp Asn
1
<210> 12
<211> 5
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 12
Asp Asp Asp Asp Asn
1 5
<210> 13
<211> 6
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 13
Asp Asp Asp Asp Asp Asn
1 5
<210> 14
<211> 7
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 14
Asp Asp Asp Asp Asp Asp Asn
1 5
<210> 15
<211> 8
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 15
Asp Asp Asp Asp Asp Asp Asp Asn
1 5
<210> 16
<211> 9
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 16
Asp Asp Asp Asp Asp Asp Asp Asp Asn
1 5
<210> 17
<211> 2
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 17
Asp Orn
1
<210> 18
<211> 3
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 18
Asp Asp Orn
1
<210> 19
<211> 4
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 19
Asp Asp Asp Orn
1
<210> 20
<211> 5
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 20
Asp Asp Asp Asp Orn
1 5
<210> 21
<211> 6
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 21
Asp Asp Asp Asp Asp Orn
1 5
<210> 22
<211> 7
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 22
Asp Asp Asp Asp Asp Asp Orn
1 5
<210> 23
<211> 8
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 23
Asp Asp Asp Asp Asp Asp Asp Orn
1 5
<210> 24
<211> 9
<212> PRT
<213>巨大芽孢杆菌（Bacillus megaterium）
<400> 24
Asp Asp Asp Asp Asp Asp Asp Asp Orn
1 5
Claims (2)
1.含鸟氨酸的短肽在固体培养基上抑制黄曲霉生长中的应用，其特征在于，所述短肽的氨基酸序列为：
Asp-Orn。
2.含鸟氨酸的短肽在农作物储存中抑制黄曲霉的生长中的应用，其特征在于，所述短肽的氨基酸序列为：
Asp-Orn。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910836442.2A CN110590919B (zh) | 2017-05-24 | 2017-05-24 | 含鸟氨酸的短肽及其应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710371944.3A CN107021996B (zh) | 2017-05-24 | 2017-05-24 | 一种短肽、其应用以及由其得到的抗菌组合物 |
| CN201910836442.2A CN110590919B (zh) | 2017-05-24 | 2017-05-24 | 含鸟氨酸的短肽及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710371944.3A Division CN107021996B (zh) | 2017-05-24 | 2017-05-24 | 一种短肽、其应用以及由其得到的抗菌组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110590919A CN110590919A (zh) | 2019-12-20 |
| CN110590919B true CN110590919B (zh) | 2022-05-24 |
Family
ID=59529853
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710371944.3A Active CN107021996B (zh) | 2017-05-24 | 2017-05-24 | 一种短肽、其应用以及由其得到的抗菌组合物 |
| CN201910836442.2A Active CN110590919B (zh) | 2017-05-24 | 2017-05-24 | 含鸟氨酸的短肽及其应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710371944.3A Active CN107021996B (zh) | 2017-05-24 | 2017-05-24 | 一种短肽、其应用以及由其得到的抗菌组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN107021996B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112661807B (zh) * | 2020-12-22 | 2021-12-28 | 中国海洋大学 | 抗菌脂肽Fengycin在抑制黄曲霉生长和毒素合成中的应用 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044102A (zh) * | 1989-01-13 | 1990-07-25 | 理查德奇特昂凡昔的古阿脱 | 抑制t—淋巴细胞成熟和巨噬细胞活性的新颖肽含有这些肽的药用组合物及其制备方法 |
| WO1991006356A1 (en) * | 1989-10-31 | 1991-05-16 | Terrapin Technologies, Inc. | Method to identify analyte-binding ligands |
| WO1992008476A1 (en) * | 1990-11-07 | 1992-05-29 | The Scripps Research Institute | Peptides that inhibit platelet binding of adhesion molecules |
| CN1520291A (zh) * | 2001-01-12 | 2004-08-11 | ���귨ķ�ɷݹ�˾ | 作为NF-κB抑制剂的富马酸衍生物 |
| CN101505784A (zh) * | 2006-03-30 | 2009-08-12 | 帕拉丁科技公司 | 环状利尿钠肽构建体 |
| CN102066413A (zh) * | 2008-01-22 | 2011-05-18 | 阿拉伊姆药品公司 | 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
| CN102863346A (zh) * | 2012-09-07 | 2013-01-09 | 宜兴市前成生物有限公司 | 一种制备l-天门冬氨酸-l-鸟氨酸的方法 |
| CN103014086A (zh) * | 2012-12-12 | 2013-04-03 | 武汉圣佳化工有限公司 | 一种酶固定化连续生产l-鸟氨酸复合盐的方法 |
| WO2013064583A1 (en) * | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| CN105154499A (zh) * | 2015-09-30 | 2015-12-16 | 精晶药业股份有限公司 | L-天门冬氨酸-l-鸟氨酸的制备方法 |
| CN107619428A (zh) * | 2017-09-22 | 2018-01-23 | 南京优科生物医药研究有限公司 | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 |
| CN112661807A (zh) * | 2020-12-22 | 2021-04-16 | 中国海洋大学 | 抗菌脂肽Fengycin在抑制黄曲霉生长和毒素合成中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051326A1 (en) * | 2004-11-12 | 2008-02-28 | Alexander Dylan C | Antiinfective Lipopeptides |
| CN104178543B (zh) * | 2013-06-25 | 2017-10-03 | 四川农业大学 | 一株黄曲霉生防菌的抗菌活性物质及其分离纯化方法 |
| CN104059129B (zh) * | 2014-06-04 | 2017-01-04 | 北京源生元科技发展有限公司 | 一种抗真菌肽及其在抑制黄曲霉毒素产生中的应用 |
-
2017
- 2017-05-24 CN CN201710371944.3A patent/CN107021996B/zh active Active
- 2017-05-24 CN CN201910836442.2A patent/CN110590919B/zh active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044102A (zh) * | 1989-01-13 | 1990-07-25 | 理查德奇特昂凡昔的古阿脱 | 抑制t—淋巴细胞成熟和巨噬细胞活性的新颖肽含有这些肽的药用组合物及其制备方法 |
| WO1991006356A1 (en) * | 1989-10-31 | 1991-05-16 | Terrapin Technologies, Inc. | Method to identify analyte-binding ligands |
| WO1992008476A1 (en) * | 1990-11-07 | 1992-05-29 | The Scripps Research Institute | Peptides that inhibit platelet binding of adhesion molecules |
| CN1520291A (zh) * | 2001-01-12 | 2004-08-11 | ���귨ķ�ɷݹ�˾ | 作为NF-κB抑制剂的富马酸衍生物 |
| CN101505784A (zh) * | 2006-03-30 | 2009-08-12 | 帕拉丁科技公司 | 环状利尿钠肽构建体 |
| CN102066413A (zh) * | 2008-01-22 | 2011-05-18 | 阿拉伊姆药品公司 | 用于预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物 |
| WO2013064583A1 (en) * | 2011-11-04 | 2013-05-10 | Lipotec, S.A. | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions |
| CN102863346A (zh) * | 2012-09-07 | 2013-01-09 | 宜兴市前成生物有限公司 | 一种制备l-天门冬氨酸-l-鸟氨酸的方法 |
| CN103014086A (zh) * | 2012-12-12 | 2013-04-03 | 武汉圣佳化工有限公司 | 一种酶固定化连续生产l-鸟氨酸复合盐的方法 |
| CN105154499A (zh) * | 2015-09-30 | 2015-12-16 | 精晶药业股份有限公司 | L-天门冬氨酸-l-鸟氨酸的制备方法 |
| CN107619428A (zh) * | 2017-09-22 | 2018-01-23 | 南京优科生物医药研究有限公司 | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 |
| CN112661807A (zh) * | 2020-12-22 | 2021-04-16 | 中国海洋大学 | 抗菌脂肽Fengycin在抑制黄曲霉生长和毒素合成中的应用 |
Non-Patent Citations (4)
| Title |
|---|
| L-α-Aspartyl-L-ornithine;CAS REGISTRY;《CAS REGISTRY》;19841116;14169-16-5 * |
| Metabolic Engineering of Saccharomyces cerevisiae for Production of Novel Cyanophycins with an Extended Range of Constituent Amino Acids;Anna Steinle等;《American Society for Microbiology》;20090601;第75卷(第11期);参见图1化合物4 * |
| The Relationship between Taste and Primary Structure of "Delicious Peptide" (Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala) from Beef Soup;Masahiro Tamura等;《Agricultural and Biological Chemistry》;19890201;第53卷(第2期);参见表1、4 * |
| Three newly identified peptides from Bacillus megaterium strongly inhibit the growth and aflatoxin B1 production of Aspergillus flavus;YujieChen等;《Food Control》;20180727;第95卷;41-49 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107021996B (zh) | 2020-02-14 |
| CN107021996A (zh) | 2017-08-08 |
| CN110590919A (zh) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Isolation and characterization of Bacillus amyloliquefaciens PG12 for the biological control of apple ring rot | |
| Passari et al. | Detection of biosynthetic gene and phytohormone production by endophytic actinobacteria associated with Solanum lycopersicum and their plant-growth-promoting effect | |
| Islam et al. | Isolation and identification of antifungal compounds from Bacillus subtilis C9 inhibiting the growth of plant pathogenic fungi | |
| Araujo et al. | Phytohormones and antibiotics produced by Bacillus subtilis and their effects on seed pathogenic fungi and on soybean root development | |
| Khan et al. | The endophytic bacteria Bacillus velezensis Lle-9, isolated from Lilium leucanthum, harbors antifungal activity and plant growth-promoting effects | |
| Nanjundan et al. | Antimicrobial activity and spectroscopic characterization of surfactin class of lipopeptides from Bacillus amyloliquefaciens SR1 | |
| CN108060100B (zh) | 一种多功能暹罗芽孢杆菌及其生物活性物质的制备和应用 | |
| Paul et al. | Assemblages of endophytic bacteria in chili pepper (Capsicum annuum L.) and their antifungal activity against phytopathogens in vitro | |
| Pan et al. | Fusarium redolens 6WBY3, an endophytic fungus isolated from Fritillaria unibracteata var. wabuensis, produces peimisine and imperialine-3β-d-glucoside | |
| CN109355233B (zh) | 一种解淀粉芽孢杆菌及其应用 | |
| Kong et al. | Production of surfactin and iturin by Bacillus licheniformis N1 responsible for plant disease control activity | |
| Yang et al. | Screening Bacillus species as biological control agents of Gaeumannomyces graminis var. tritici on wheat | |
| Kumar et al. | Antagonistic activity of lipopeptide-biosurfactant producing Bacillus subtilis AKP, against Colletotrichum capsici, the causal organism of anthracnose disease of chilli | |
| George et al. | Plant growth promoting endophytic yeast Geotrichum candidum (JX 477426) from roots of Bruguiera cylindrica. | |
| Cheng et al. | Endophytic Bacillus subtilis MJMP2 from Kimchi inhibits Xanthomonas oryzae pv. oryzae, the pathogen of Rice bacterial blight disease | |
| CN110024696B (zh) | 黄盖小脆柄菇及在制备天然抑菌剂中的应用 | |
| CN110590919B (zh) | 含鸟氨酸的短肽及其应用 | |
| Chen et al. | Biocontrol of Fusarium wilt disease in strawberries using bioorganic fertilizer fortified with Bacillus licheniformis X-1 and Bacillus methylotrophicus Z-1 | |
| CN105722396A (zh) | 分离的链霉菌属细菌 | |
| He et al. | Identification of lipopeptides produced by Bacillus subtilis Czk1 isolated from the aerial roots of rubber trees | |
| Bidima et al. | Antifungal activity of bioactive compounds produced by the endophyte Bacillus velezensis NC318 against the soil borne pathogen Sclerotium rolfsii Sacc | |
| CN114672440B (zh) | 枯草芽孢杆菌bs273及其应用 | |
| KR20180001716A (ko) | 바실러스 서브틸리스 배양액 추출물을 포함하는 세균성 마름병 방제용 항균 조성물 | |
| KR102612464B1 (ko) | 담수에서 분리한 항균력 및 식물생장촉진능을 가지는 아크레모니움 투바키 nnibrfg2982 균주 및 이의 용도 | |
| Vijay et al. | Biosurfactant lipopeptides and polyketide biosynthetic gene in rhizobacterium Achromobacter kerstersii to induce systemic resistance in tomatoes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |